Amosulalol - Astellas Pharma/LTL Pharma
Alternative Names: Lowgan; LY 137224; YM 09538Latest Information Update: 07 Dec 2017
At a glance
- Originator Astellas Pharma
- Developer Astellas Pharma; LTL Pharma
- Class Antihypertensives; Ethanolamines; Small molecules; Sulfonamides
- Mechanism of Action Alpha beta adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypertension
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 05 Jul 1999 No-Development-Reported for Hypertension in South Korea (PO)
- 05 Jul 1999 No-Development-Reported for Hypertension in United Kingdom (PO)